Author

D. Connolly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

J. Westermarck· 2 shared T. Gronroos· 2 shared U. Butt· 2 shared A. Cvrljevic· 1 shared A. Laine· 1 shared A. N. Cvrljevic· 1 shared A. Ristimaki· 1 shared B. Uhal· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTS

B. Uhal, N. M. Bodie, D. Connolly, J. Chu

This paper designs a chimeric ACE-2/Fc-silent fusion protein with ultra-high affinity and neutralizing capacity against multiple SARS-CoV-2 variants.

Antibody Therapeutics · Jan 18, 2023Peer-reviewedMicrobiology

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck

The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.

bioRxiv · Mar 31, 2021Cancer Biology

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

A. Laine, S. Nagelli, C. Farrington, U. Butt, A. Cvrljevic, J. Vainonen, T. Gronroos, P. Gautam, S. Khan, H. Sihto, X. Qiao, D. Connolly, P. Kronqvist, J. Maurer, K. Wennerberg, , J. Westermarck

This study identifies CIP2A as a subtype-specific driver of DNA damage-induced basal-like breast cancer, showing its role in checkpoint signaling and therapeutic vulnerability.

bioRxiv · Aug 27, 2020Cancer Biology